Cash Flow from Operating Activities: A company's cash flows from operations.
Alnylam Pharmaceuticals, Inc. (ALNY) had Cash Flow from Operating Activities of $360.52M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$1.25B |
|
$251.08M |
|
$200.15M |
|
$1.05B |
|
$881.04M |
|
$367.98M |
|
$-129.01M |
|
$238.97M |
|
$238.97M |
|
$251.08M |
|
$251.08M |
|
$251.08M |
|
$251.08M |
|
$367.98M |
|
$381.79M |
|
131.45M |
|
137.35M |
|
$1.91 |
|
$1.84 |
|
| Balance Sheet Financials | |
$3.95B |
|
$501.75M |
|
$898.85M |
|
$4.85B |
|
$1.56B |
|
$1.04B |
|
$3.06B |
|
$4.62B |
|
$233.89M |
|
$233.89M |
|
$233.89M |
|
131.79M |
|
| Cash Flow Statement Financials | |
|
Cash Flow from Operating Activities |
$360.52M |
$473.50M |
|
$-350.51M |
|
$968.65M |
|
$1.49B |
|
$524.15M |
|
$276.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.54 |
|
-- |
|
-- |
|
0.82 |
|
4.45 |
|
83.98% |
|
29.46% |
|
29.46% |
|
-- |
|
19.13% |
|
20.10% |
|
$325.12M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
2.66 |
|
1.29 |
|
69.52 |
|
107.35% |
|
107.35% |
|
5.18% |
|
19.71% |
|
$1.77 |
|
$2.37 |
|
$2.62 |
|